Introduction
The cysteine-rich protein 61 (Cyr61, CCN1), a member of the CCN-family, is a matricellular protein expressed and secreted by various cells. Among other actions, Cyr61 induces angiogenetic effects and enhances the tumorigenicity of solid tumors [1] . Cyr61 also mediates the adhesion and migration of tumor cells by interaction with various members of the integrin adhesion family. Integrins are heterodimeric cell surface proteins which are involved in the steps of metastasis e.g. adhesion, migration and connecting inside and outside cell signals. Therefore, Cyr61 appears to have a key role in the function of integrin making Cyr61 an attractive target for interferring with tumor cell metastasis. However, these theoretical aspects are far from well understood.
The prostate cancer cell line PC-3, known to express Cyr61, was selected for functional in vitro studies. Our data provide evidence that Cyr61 has a clear impact on cell migration via alteration of the functions of integrin.
Material and methods

Drugs and reagents
Antibodies for flow cytometric analysis against human integrin subunits α 1 , α 5 , α V , β 3 were purchased from R&D-Systems and α 4 from Elan Pharma, (Monksland, Ireland) (Tysabri ® ). Secondary FITC-labeled antibodies were obtained from R&D-Systems and Sigma-Aldrich. Fibronectin (20.8 µg/ml) and collagen Type 1 (10 µg/ml) were obtained from Roche Applied Science. Antibodies for western blotting were purchased from Santa Cruz (anti Cyr61) and BD (anti integrin α 5 , anti β-actin and secondary antibody HRP conjugated against mouse Fc chimera)
Cell culture and transfection
The human prostate cancer cell line PC-3 was obtained from ATCC (CRL-1435™) cultured in RPMI 1640 (PAN) containing 10% FCS (Sigma-Aldrich), 1% GlutaMAX™, 2% HEPES, 1% penicillin/streptomycin (all obtained from Invitrogen); at 37 °C, 95% air/5% CO 2 . PC-3 cells were transfected by using a commercial shRNA-Plasmid (Mission ® shRNA, Sigma-Aldrich (Taufkirchen, Germany)), recovered by Maxi-Prep (Sigma-Aldrich) of E. coli. Lipid-based transfection of PC-3 cells was carried out by using FuGene ® 6 (Roche Applied Science (Mannheim, Germany)), efficient DNA-lipid concentration was previously tested by GFPPlasmid transfection. After transfection, cells stably expressing antiCyr61-shRNA were selected by puromycin (Applichem) treatment.
Fluorescent cell staining
Integrin expression of PC-3 cells was quantified via flow cytometry using a FACSCalibur (BD Biosciences (Heidelberg, Germany)), software CellQuest TM Pro Version 5.2.1 (BD Biosciences) and the indicated antibodies and fluorescently labeled secondary antibodies.
Western blotting
Western blotting was carried out by using 50 µg of whole protein lysate. Proteins were separated by SDS-PAGE with a 10% resolving gel under denaturating conditions and proteins were transferred by tank-blot procedure on a PVDF membrane. Subsequent blocking the membrane with 5% skinny milk solution the incubation of the primary antibody followed overnight. After washing the membrane threefold, it was incubated for 2 hours with secondary horse radish peroxidase conjugated antibody and finally chemiluminescense was detected.
Migration assay
Cell migration assays were performed according to Liang et al. [2] . Briefly, PC-3 wild type and PC-3 Cyr61 knock down cells were detached and washed in PBS, centrifuged and resuspended in medium. 1 × 10 5 cells per well were seeded on 6-well flask and cultured on fibronectin or collagen Type 1 to simulate the extracellular matrix. After 8 hours the cells were adhered to the surface and detached at a single spot by scraping with a pipette tip to create a gap. Microscopic images of the scratch were taken in intervals of two hours with the microscope Axiovert 200 (Carl Zeiss AG, Jena, Germany). Differences between wild type and clone cells were examined by migration speed analyses. For analysis the distance between the cell fronts was measured at three spots and the mean of the values was plotted against the time. On the basis of these coordinates a linear graph with the formula f(x) = a × x + b was received for each approach and negative slopes or velocities result from the decreasing width between the cells. The experiments were repeated for at least three times and were analyzed with the software GraphPad Prism ® .
Results
Cyr61 knock down in PC-3 prostate cancer cells
In order to investigate the impact of Cyr61 on integrin activity, a Cyr61 knock down clone type of PC-3 prostate cancer cells was established by shRNA technology. The clone cells displayed a 75% reduction in 
Integrin status of wild vs. clone type cells
The 2-D migration of cells onto different matrices is mainly mediated by the adhesion receptor family of integrins showing a certain redundancy in substrate recognition. To obtain an insight into the integrin expression of PC-3 cells and to check if the shRNA transfection had an impact on integrin pattern, selected integrin subunit expression (α 1 , α 4 , α 5 , α V and β 3 ) were tested by flow cytometry and Western blotting. There was only one major difference between wild type and clone type cells. Clone cells exhibit a higher expression of α 5 than wild type cells ( Figure 1A ). This finding has to be considered with respect to potential integrin activation by Cyr61.
Migration scratch assay
The wild type cells migrate significantly faster than the clone cells on noncoated surfaces. This is a first indication for reduced integrin activity in the clone type cells, however, it cannot be related to specific integrin subunits. Although there are also visual differences evident indicating a slower migration of the clone cells on fibronectin ( Figure 1B) , significance could not be reached considering all data (Figure 1C) . The wound healing assay, used here for evaluating cell migration capacities, is an experimentally excepted assay, although impaired by several experimental parameters, such as initial cell density or scratch width. The detection of a velocity slope appears as a sufficient parameter to differentiate the migratory capacities. These migration data onto fibronectin are affected by the much higher expression of the α 5 integrin subunit in the clone cells, since α 5 β 1 is the main fibronectin receptor. Consequently, the lack in Cyr61 mediated integrin activation in the clone cells appears to be equilibrated by a higher receptor expression.
The cell migration on collagen further emphasizes the relevance of Cyr61 on the integrin activation. The collagen binding receptor subunit α 1 is expressed in the same amount by both cell types. Thus, the migration on collagen is just influenced by different Cyr61 activities. As indicated in Figure  1C , this impact of Cyr61 is clearly revealed by the migration velocity data (wild type: -22.44 µm/h; clone type: -17.99 µm/h) although the effect is not statistically significant.
Conclusion
The matricellular protein Cyr61 possesses manifold effects in tumorigenicity, partly via activating integrin function. Integrins are important, e.g. for cell migratory activities in term of the metastatic cascade of tumor cells. Here we provide further evidence, using the PC-3 prostate cancer cells and its Cyr61 knock-out clone that Cyr61 can affect the integrin function in cell migration.
Concerning the migration on collagen, the lack in Cyr61 clearly influences the migratory velocity of PC-3 cells (wild type -22.44 µm/h vs. clone type -17.99 µm/h). Unfortunately, a potential reduction in cell migration of the clones on fibronectin was compensated by the much higher expression of the fibronectin receptor subunit α 5 . However, these data support previous reports on the tumorigenicity of Cyr61 and add novel insight into the Cyr61-dependency of PC-3 prostate cancer cells.
Consequently, Cyr61 appears as an attractive novel target for interferring with the metastatic functions of integrins, such as cell adhesion in the vasculature and at distant sites from the primary tumor or transmigration in the ECM [3] . Since Cyr61 binds to heparin, which is frequently used in malignant diseases for antithrombotic prophylaxis, a heparin interference with Cyr61 activities opens novel therapeutic options and potential targets of heparin. Preliminary data on the effects of heparin on the migration of PC-3 cells on collagen support this assumption and the need for further investigations in this field.
